



Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences

May 1, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2017-- Seres Therapeutics Inc. (NASDAQ:MCRB) today announced that management will participate in two upcoming investor conferences:

- Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16, 2017 in Las Vegas, NV; presentation at 3 p.m. PDT.
- UBS Global Healthcare Conference on Monday, May 22, 2017 in New York, NY; presentation at 1:30 p.m. EDT.

Live audio webcast of the presentations will be available under the "Investors and Media" section of Seres' website. A replay of the presentations will become available after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. A Phase 2 study of Seres' program SER-109 has been completed in multiply recurrent *Clostridium difficile* infection. Seres' clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI. For more information, please visit www.serestherapeutics.com. Follow us on Twitter [@SeresTx](https://twitter.com/SeresTx).



View source version on businesswire.com: <http://www.businesswire.com/news/home/20170501005134/en/>

Source: Seres Therapeutics Inc.

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
ctanzi@serestherapeutics.com